Hubertus Erlen, chief executive of Germany’s Schering AG, is expecting a new anti-cancer agent – PTK/ZK – currently under development with Novartis, to become a blockbuster drug, with annual sales in excess of one billion euros.
Read MoreWyeth has lost the second phase of a two-phase trial, with the judge ruling in favour of three women who claim to have suffered heart valve damage as a result of taking the company’s now withdrawn Pondimin (fenfluramine) diet drug.
Read MoreForest Laboratories, which last month cut its outlook for the full-year 2005 as a result of generic competition to its top-selling antidepressant, Celexa (citalopram) [[02/11/04e]], says that it is expecting its third quarter performance to exceed current expectations by around 15% as a result of stronger drug sales.
Read MoreThe world’s largest pharmaceutical company, Pfizer, has signed a research collaboration with biosciences firm, Sangamo, for the production of enhanced proteins.
Read MoreAcambis’ smallpox vaccine, ACAM2000, has been granted US Food and Drug Administration fast track designation. Investors sent the company’s share price up by more than 2% during trading on the London Stock Exchange yesterday on the news, which will speed up the product’s approval process.
Read More
